The Diabetes Patient Advocacy Coalition and Diabetes Leadership Council unite patients, employers, policymakers and the broader diabetes community to influence policies that protect patients. Despite their meaningful work for the chronic disease community, recognition of their brand, leaders and initiatives remained low. 

DPAC and DLC partnered with CURA to curate and elevate their brands among policymakers and patients.

An estimated 35,000 patients in the United States are born with a single ventricle — one of the most complex heart defects. Currently, there are no FDA-approved therapies available for this patient population. Mezzion is conducting a Phase 3 clinical trial to evaluate whether its treatment can preserve and extend cardiac function. CURA has partnered with Mezzion to elevate their presence in the congenital heart disease community to strengthen their credibility and accelerate trial recruitment.

Nearly one in four patients admitted to U.S. hospitals experience preventable harm. The Leapfrog Group (LFG), a national nonprofit organization driving a public health and policy movement in patient safety, engaged CURA Strategies to become their agency of record with the ultimate goal of increasing the public’s awareness of patient safety and the importance of hospital transparency to improve outcomes.

The American College of Cardiology (ACC) is one of the largest cardiovascular medical societies in the world with over 54,000 members.

ACC partnered with CURA to to raise its profile as the leading source for cutting-edge cardiovascular science while expanding its media footprint beyond traditional medical trade outlets.

With one in five Americans living with mental illness, the Kennedy Forum believed it was critical that mental health reform took prominence in policy discussions during the 2020 election season. The Kennedy Forum sought CURA’s support in building a movement that would bring mental health and addiction reform to the forefront of national policy talks.

More than half of Rockford, Illinois’ population live in areas with the highest social vulnerability scores—

primarily Black and Latinx communities disproportionately impacted by COVID-19. With support from the Mayor’s office, the City of Rockford partnered with CURA and the University of Illinois Chicago to secure a $3.6 million HHS Office of Minority Health grant to improve local health literacy, vaccine uptake and community trust in health care providers.

Nearly 50% of Americans are unaware that radiation therapy (RT) can cure cancer, and the media isn’t helping. Sensationalized coverage continues to fuel fear around viable treatment options.

In partnership with the American Society for Radiation Oncology (ASTRO), CURA built a branded awareness campaign to change negative perception of radiation therapy. Centered around honest, balanced perspectives of cancer survivors and radiation oncologists, the campaign challenged misconceptions and raised awareness of the curative potential of radiation therapy.

CURA helped CareDx, a leader in advanced transplant diagnostics, successfully push for the 2020 passage of a bill that languished for 16 years — the Comprehensive Immunosuppressive Drug Coverage For Kidney Transplant Patients Act.

After that success, CareDx engaged CURA to help communicate the value of their tests to payers, whose private coverage lagged behind that of Medicare. In 2023, a private Medicare contractor proposed severely restricting coverage. Developed without transplant community input, the policy created confusion and threatened patient access to critical tools across the entirety of Medicare.

Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on CAR T-cell therapy for autoimmune conditions, sought a partner to support their stakeholder engagement and clinical trial recruitment efforts. 

CURA partnered with Kyverna to engage leading patient influencers in the autoimmune space to increase awareness of CAR T-cell therapy and Kyverna’s work. This resulted in lasting partnerships and increased engagement among high-value patient communities.

New scientific advances and regulatory flexibility sparked a wave of innovation in rare kidney disease, which had seen no new treatments in 80 years. Travere Therapeutics engaged CURA for several projects over the last five years to educate public and private policymakers and influencers. Through stakeholder roundtables, consensus reports, Hill events and issue briefs, CURA has helped champion the New Era of Preventing End-Stage Kidney Disease Act.